Healthcare / Medical DevicesNasdaqGS
$12.65
-0.62 (-4.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-83.0M · quality 28.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$863M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-58.9%
↓Gross Margin
46.7%
↓Debt/Equity
1.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+13.2%
FCF CAGR
—
FCF margin
-3.0%
FCF / Net income
0.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.73B · net income $-1.13B · FCF $-83.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $2.73B | $2.73B | $2.78B | $3.00B | $3.27B | $1.66B |
| Net Income | $-1.13B | $-1.13B | $-2.05B | $-10.1M | $548.7M | $810.3M |
| EBITDA | $-482.6M | $-482.6M | $-1.49B | $607.0M | $1.09B | $1.11B |
| EPS | — | — | -30.16 | -0.15 | 9.56 | 18.60 |
| Gross Margin | 46.7% | 46.7% | 46.2% | 49.9% | 59.3% | — |
| Operating Margin | 2.0% | 2.0% | 1.6% | 8.6% | 30.1% | 63.8% |
| Net Margin | -41.5% | -41.5% | -73.7% | -0.3% | 16.8% | 48.8% |
| Balance Sheet | ||||||
| Debt/Equity | 1.48 | 1.48 | 0.90 | 0.52 | 0.58 | — |
| Current Ratio | 1.43 | 1.43 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-83.0M | $-83.0M | $-112.1M | $70.9M | $744.4M | $564.8M |
| Returns | ||||||
| ROE | -58.9% | -58.9% | -68.8% | -0.2% | 11.1% | 60.8% |
| Valuation | ||||||
| P/E | — | — | — | — | 9.49 | — |
| EV/EBITDA | — | — | — | 12.23 | 7.10 | — |
| P/B | 0.45 | 0.45 | 1.05 | 0.98 | 1.06 | — |
| Growth & Yield | ||||||
| Revenue Growth | -1.9% | -1.9% | -7.2% | -8.2% | — | — |
| EPS Growth | — | — | -20006.7% | -101.6% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-30.16 → n/d
Residual
-57.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.